QualityStocksNewsBreaks – Finovate Shares FinovateFall Agenda Highlights

 Finovate, a research and events company focused on innovation in financial and banking technology, is hosting FinovateFall, a pioneering fintech conference focused on the digital future of financial institutions. The event is slated for Sept. 9–11, 2024, in New York City. According to the announcement, the three-day fintech conference is “by and for executives and thought leaders who are revolutionizing the financial services industry.”

The event agenda includes presentations from more than 120 renowned speakers and subject matter experts and more than 60-plus live product demonstrations from a range of fintech companies, including startups to established players. Speakers for the event include Ben Maxim, chief digital strategy and innovation officer, MSU Federal Credit Union; Christopher Hollins, head of solutions sales and delivery, Silicon Valley Bank; Eric McCabe, senior vice president and head of embedded finance, Citizens Bank; Akita Somani, SVP BNPL/POS lending, U.S. Bank; Mary Joseph, vice president of strategic investments and TTS, Citi; and many other well-respected industry leaders.

To register for this event, visit https://ibn.fm/E1jvQ

To view the full press release, visit https://ibn.fm/FCM2t

About Finovate

Finovate is a research and events firm focused on innovation in financial and banking technology. Its team runs the Finovate conference series and authors the popular Finovate blog. Finovate is the only conference series focused exclusively on showcasing the best and most innovative new financial and banking technologies. Finovate conferences consistently attract large, high-impact audiences of senior financial and banking executives, venture capitalists, press, industry analysts, bloggers, regulators and entrepreneurs. For more information about the company, visit www.Finovate.com.

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks – Blockchain Futurist Conference Plays Pivotal Role in Shaping the Future of Web3, Finance

 Blockchain Futurist Conference is Canada’s largest and most high-profile Web3, blockchain and cryptocurrency event. Serving as an essential platform for ideas and collaboration, the conference has proven to be an important global gathering helping shape the future of Web3. This year’s event is scheduled for August 13-14, 2024, in Toronto, Canada; the event will run alongside ETHToronto and ETHWomen Hackathons, the largest web3 hackathons in Canada. During Futurist 2023, reporter Daniel Bruno solicited quotes from onsite attendees experiencing the excitement of the event. What they said sets the tone for this year’s dynamic must-attend Blockchain Futurist Conference. “We have attended as a sponsor since the inception, and we can see the momentum growing. We think this is the best and only event in Canada that gives everyone an opportunity to learn about crypto and Web3,” said Peter I of VirgoCX.

To view the full article, visit https://ibn.fm/dii6b

About Blockchain Futurist Conference

Untraceable’s Blockchain Futurist Conference is Canada’s largest and most high-profile blockchain and cryptocurrency event. Like no other conference, this annual event is tailored to foster engagement from its participants with hands on technology weaved into every aspect of the conference. The event brings together a global audience of attendees, including startups, investors, developers, enterprise leaders, financial institutions, researchers, academics, and emerging tech pioneers, to build the future. Attendees can expect to hear leading experts discuss trends, showcase the newest tech and debate topics that are sure to shape this technological revolution. For more information about the event, please visit www.FuturistConference.com.

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering

 Ocugen (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines, has closed on its previously announced underwritten public offering. The offering was comprised of 30,434,783 shares of its common stock, with each share sold at $1.15 per share. The company is anticipated to receive an estimated $35 million in gross proceeds, before standard deductions and expenses are made. Ocugen plans to use the funds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/ZQPpI

About Ocugen Inc.

Ocugen is a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company is making an impact on patient’s lives through courageous innovation, forging new scientific paths that harness its unique intellectual and human capital. Ocugen’s breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and the company is advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.

To learn more about the company, visit www.Ocugen.com.

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

 

• Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
• CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
• ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and utilization, driving critical cellular reactions that promote neuroprotection and remyelination, thereby enhancing neuronal and glial resilience to disease-related stressors.

In a recent Xtalks podcast, Clene discussed the significant developments of CNM-Au8 and its unique technology. CNM-Au8’s mechanism of action involves the conversion of critical energetic metabolites within living cells to produce ATP, the essential energy currency for cellular functions. The gold nanocrystals attract a coating of apolipoproteins from human plasma, facilitating their passage through the blood-brain barrier and into the brain, where they can protect neurons from death and repair damaged neurons by catalyzing energy production (https://ibn.fm/Gvb5o).

CNM-Au8 is being evaluated in multiple clinical trials, including the prestigious Harvard/MGH HEALEY ALS Platform Trial, which targets patients with mid-to-late stage ALS. The drug has also completed the RESCUE-ALS proof-of-concept clinical trial for early symptomatic ALS, and the REPAIR trials, showing promising changes in brain energy metabolites with CNM-Au8 administration. Additionally, CNM-Au8 has completed a clinical trial, VISIONARY-MS, for treating visual pathway deficits in chronic optic neuropathy, demonstrating its potential for remyelination in stable relapsing MS.

With more than 650 estimated years of collective exposure across ALS, MS, and PD participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs, CNM-Au8 has shown a robust safety profile without any observed safety signals. The drug is designed to be used in combination with other agents and has no known drug-drug interactions, making it a versatile option for patients.

ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide. Clene estimates that global ALS treatment sales will exceed $1 billion annually in the coming years, underscoring the urgent need for viable treatment options.

Founded in 2013 and based in Salt Lake City, Utah, Clene Inc. is at the forefront of developing innovative treatments for neurodegenerative diseases. With research and development, as well as manufacturing operations in Maryland, Clene is committed to transforming the treatment landscape for ALS, MS, PD, and other debilitating conditions through its groundbreaking nanotherapeutic platform.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN